Franklin Biotechnology Discovery Fund Z(acc)GBP

Register to Unlock Ratings
Performance History30/11/2021
Growth of 1,000 (GBP) Advanced Graph
Franklin Biotechnology Discovery Fund Z(acc)GBP
Fund7.2-10.929.224.1-14.7
+/-Cat-3.1-3.09.0-1.8-7.6
+/-B’mrk-3.9-7.78.91.6-19.3
 
Key Stats
NAV
03/12/2021
 GBP 36.09
Day Change -2.51%
Morningstar Category™ Sector Equity Biotechnology
IA (formerly IMA) Sector -
ISIN LU0774687577
Fund Size (Mil)
31/10/2021
 USD 2351.76
Share Class Size (Mil)
29/10/2021
 GBP 5.65
Max Initial Charge -
Ongoing Charge
24/01/2021
  1.33%
Morningstar Research
Analyst Report

Franklin Biotechnology Discovery benefits from an experienced team, but limited resources and an undifferentiated process earn the fund a Morningstar Analyst Rating of Neutral.This strategy was caught flat-footed in 2021, and its poor performance...

Click here to read this analyst report on the underlying fund.
Morningstar Pillars
PeopleAverage
ParentAverage
ProcessAverage
Performance
Price
Investment Objective: Franklin Biotechnology Discovery Fund Z(acc)GBP
The Fund invests principally in equity securities of biotechnology companies and discovery research firms located in the US and other countries and to a lesser extent in debt securities of any type of issuers worldwide. For the Fund’s investment purposes, a biotechnology company is one that has at least 50% of its earnings derived from biotechnology activities, or at least 50% of its assets devoted to such activities based on the company’s most recent fiscal year. Biotechnology activities are research, development, manufacture, and distribution of various biotechnological or biomedical products, services and processes. This may include companies involved with genomics, genetic engineering, and gene therapy. It also includes companies involved in the application and development of biotechnology in areas such as health care, pharmaceuticals, and agriculture.
Returns
Trailing Returns (GBP)03/12/2021
YTD-17.62
3 Years Annualised4.55
5 Years Annualised4.97
10 Years Annualised-
12 Month Yield 0.00
Management
Manager Name
Start Date
Evan McCulloch
01/11/2000
Wendy Lam
01/09/2018
Click here to see others
Inception Date
04/05/2012
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR USDNASDAQ Biotechnology TR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNot Specific
GrowthYes
IncomeNot Specific
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  Franklin Biotechnology Discovery Fund Z(acc)GBP31/10/2021
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock94.340.0094.34
Bond0.210.000.21
Property0.000.000.00
Cash5.070.005.07
Other0.390.000.39
Top 5 Regions%
United States92.95
Asia - Emerging3.09
United Kingdom1.77
Canada1.00
Europe - ex Euro0.75
Top 5 Sectors%
Healthcare98.31
Financial Services1.69
Top 5 HoldingsSector%
Regeneron Pharmaceuticals IncHealthcareHealthcare5.53
Amgen IncHealthcareHealthcare4.65
Horizon Therapeutics PLCHealthcareHealthcare4.54
Illumina IncHealthcareHealthcare4.42
Gilead Sciences IncHealthcareHealthcare4.31
Franklin Biotechnology Discovery Fund Z(acc)GBP

Related

In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)